

12-21-01

EXPRESS MAIL NO: EL897371937US

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**(To be used for all correspondence  
after initial filing)



Application Number	09/685,830
Filing Date	October 9, 2000
First Named Inventor	Alexander Gaiger
Group Art Unit	1644
Examiner Name	Ronald Schwadron
Attorney Docket No.	210121.465C3

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <u>Computer disk, Copy of Notice to Comply, Paper Copy of Sequence Listing, Declaration regarding disk.</u>
--	---	---


Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Jeffrey Hundley, Ph.D. 42,676	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	December 17, 2001	

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage via Express Mail with label number EL897371937US in an envelope addressed to: Commissioner for Patents, Washington D.C. 20231 on the date specified below.

Typed or printed name	Monica Steinborn	
Signature		Date: December 17, 2001

TECH CENTER 1600/2900

DEC 27 2001

RECEIVED

1644

Box 509



1

EXPRESS MAIL NO: EL897871937US

PATENT

#6/a  
Harry  
Dec 29, 01

TECH CENTER 1600/2900

DEC 27 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger and Martin A. Cheever  
Application No. : 09/685,830  
Filed : October 9, 2000  
For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC  
IMMUNOTHERAPY

Examiner : Ronald Schwadron  
Art Unit : 1644  
Docket No. : 210121.465C3  
Date : December 17, 2001

Commissioner for Patents  
Washington D.C. 20231

PRELIMINARY AMENDMENT REGARDING SEQUENCE DISCLOSURES

Commissioner for Patents:

In response to the Communication from the Examiner dated December 5, 2001,  
please amend the above-identified application as follows:

In the Specification:

Please delete the section of the application entitled "Sequence Listing" immediately  
after the section of the specification entitled "Abstract of the Disclosure" on page 128 and insert the  
enclosed Sequence Listing therefor.